Dual-modified PCL-PEG nanoparticles for improved targeting and therapeutic efficacy of docetaxel against colorectal cancer

References

• Baker DSD, Sparreboom A, Verweij J. 2006. Clinical pharmacokinetics of docetaxel: recent developments. Clin Pharmacokinet. 45(3):235–252.
   PubMed Web of Science ®Google Scholar
• Baker J, Ajani J, Scotté F, Winther D, Martin M, Aapro MS, von Minckwitz G. 2009. Docetaxel-related side effects and their management. Eur J Oncol Nurs. 13(1):49–59.
   PubMed Web of Science ®Google Scholar
• Barenholz Y. 2012. Doxil®-the first FDA-approved nano-drug: lessons learned. J Control Release. 160(2):117–134.
   PubMed Web of Science ®Google Scholar
• Brody H. 2015. Colorectal cancer. Nature. 521(7551):S1.
   PubMed Web of Science ®Google Scholar
• Cho HJ, Yoon HY, Koo H, Ko SH, Shim JS, Lee JH, Kim K, Kwon IC, Kim DD. 2011. Self-assembled nanoparticles based on hyaluronic acid-ceramide (HA-CE) and Pluronic® for tumor-targeted delivery of docetaxel. Biomaterials. 32(29):7181–7190.
   PubMed Web of Science ®Google Scholar
• Conner SD, Schmid SL. 2003. Regulated portals of entry into the cell. Nature. 422(6927):37–44.
   PubMed Web of Science ®Google Scholar
• Lumen D, Näkki S, Imlimthan S, Lambidis E, Sarparanta M, Xu W, Lehto V-P, Airaksinen AJ. 2019. Site-specific 111 in-radiolabeling of dual-PEGylated porous silicon nanoparticles and their in vivo evaluation in murine 4T1 breast cancer model. Pharmaceutics. 11(12):686.
   Web of Science ®Google Scholar
• Debbage P. 2009. Targeted drugs and nanomedicine: present and future. Curr Pharm Des. 15(2):153–172.
   PubMed Web of Science ®Google Scholar
• Demeule M, Currie JC, Bertrand Y, Ch C, Nguyen T, Régina A, Gabathuler R, Castaigne JP, Béliveau R. 2008. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector Angiopep-2. J Neurochem. 106(4):1534–1544.
   PubMed Web of Science ®Google Scholar
• Engels FK, Mathot RAA, Verweij J. 2007. Alternative drug formulations of docetaxel: a review. Anticancer Drugs. 18(2):95–103.
   PubMed Web of Science ®Google Scholar
• Esmaeili F, Dinarvand R, Ghahremani MH, Amini M, Rouhani H, Sepehri N, Ostad SN, Atyabi F. 2009. Docetaxel-albumin conjugates: preparation, in vitro evaluation and biodistribution studies. J Pharm Sci. 98(8):2718–2730.
   PubMed Web of Science ®Google Scholar
• Fang J, Nakamura H, Maeda H. 2011. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 63(3):136–151.
   PubMed Web of Science ®Google Scholar
• Florence TA. 2012. "Targeting" nanoparticles: the constraints of physical laws and physical barriers”. J Control Release. 164(2):115–124.
   PubMed Web of Science ®Google Scholar
• Fotiadis D, Kanai Y, Palacín M. 2013. The SLC3 and SLC7 families of amino acid transporters. Mol Aspects Med. 34(2-3):139–158.
   PubMed Web of Science ®Google Scholar
• Gao H, Yang Z, Zhang S, Cao S, Shen S, Pang Z, Jiang X. 2013. Ligand modified nanoparticles increases cell uptake, alters endocytosis and elevates glioma distribution and internalization. Sci Rep. 3:2534.
   PubMed Web of Science ®Google Scholar
• Gaucher G, Dufresne M-H, Sant VP, Kang N, Maysinger D, Leroux J-C. 2005. Block copolymer micelles: preparation, characterization and application in drug delivery. J Control Release. 109(1-3):169–188.
   PubMed Web of Science ®Google Scholar
• He C, Hu Y, Yin L, Tang C, Yin C. 2010. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials. 31(13):3657–3666.
   PubMed Web of Science ®Google Scholar
• Immordino ML, Brusa P, Arpicco S, Stella B, Dosio F, Cattel L. 2003. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. J Control Release. 91(3):417–429.
   PubMed Web of Science ®Google Scholar
• Ito S, Ohtsuki S, Terasaki T. 2006. Functional characterization of the brain-to-blood efflux clearance of human amyloid-beta peptide (1-40) across the rat blood-brain barrier. Neurosci Res. 56(3):246–252.
   PubMed Web of Science ®Google Scholar
• Peng J, Chen J, Xie F, Bao W, Xu H, Wang H, Xu Y, Du Z. 2019. Herceptin-conjugated paclitaxel loaded PCL-PEG worm-like nanocrystal micelles for the combinatorial treatment of HER2-positive breast cancer. Biomaterials. 222:119420.
   PubMed Web of Science ®Google Scholar
• Jianwei D, Chao L, Xiaoyu L, Xuanling L, Youlu C, Zuoguan C, Xiaoli W, Deling K, Yongjun L, Jing Y. 2018. Protein delivery nanosystem of six-arm copolymer poly(ε-caprolactone)-poly(ethylene glycol) for long-term sustained release. Int J Nanomedicine. 13:2743–2754.
   PubMed Web of Science ®Google Scholar
• Jordan M, Kamath K. 2007. How do microtubule-targeted drugs work? An overview. Curr Cancer Drug Targets. 7(8):730–742.
   PubMed Web of Science ®Google Scholar
• Kanai Y, Segawa H, Miyamoto K. i, Uchino H, Takeda E, Endou H. 1998. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem. 273(37):23629–23632.
   PubMed Web of Science ®Google Scholar
• Lammers T, Kiessling F, Hennink WE, Storm G. 2012. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release. 161(2):175–187.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Jeong B. 2020. ROS-sensitive degradable PEG-PCL-PEG micellar thermogel. Small. 16(12):1903045.
   Web of Science ®Google Scholar
• Lyseng-Williamson KA, Fenton C. 2005. Docetaxel: a review of its use in metastatic breast cancer. Drugs. 65(17):2513–2531.
   PubMed Web of Science ®Google Scholar
• Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. 2000. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 65(1-2):271–284.
   PubMed Web of Science ®Google Scholar
• Maletínská L, Blakely EA, Bjornstad KA, Deen DF, Knoff LJ, Forte TM. 2000. Human glioblastoma cell lines: levels of low-density lipoprotein receptor and low-density lipoprotein receptor-related protein. Cancer Res. 60(8):2300–2303.
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Maeda H. 1986. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res. 46(12 Pt 1):6387–6392.
   PubMed Web of Science ®Google Scholar
• Meel RVD, Vehmeijer LJC, Kok RJ, Storm G, Gaal EVBV. 2016. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status. International Publishing: Springer.
   Google Scholar
• Michael A, Syrigos K, Pandha H. 2009. Prostate cancer chemotherapy in the era of targeted therapy. Prostate Cancer Prostatic Dis. 12(1):13–16.
   PubMed Web of Science ®Google Scholar
• Mousa SA, Bharali DJ. 2011. Nanotechnology-based detection and targeted therapy in cancer: nano-bio paradigms and applications. Cancers. 3(3):2888–2903.
   PubMedGoogle Scholar
• Mu CF, Balakrishnan P, Cui F-D, Yin Y-M, Lee Y-B, Choi H-G, Yong CS, Chung S-J, Shim C-K, Kim D-D. 2010. The effects of mixed MPEG-PLA/Pluronic copolymer micelles on the bioavailability and multidrug resistance of docetaxel. Biomaterials. 31(8):2371–2379.
   PubMed Web of Science ®Google Scholar
• Persohn E, Canta A, Schoepfer S, Traebert M, Mueller L, Gilardini A, Galbiati S, Nicolini G, Scuteri A, Lanzani F, et al. 2005. Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats. Eur J Cancer. 41(10):1460–1466.
   PubMed Web of Science ®Google Scholar
• Rautio J, Gynther M, Laine K. 2013. LAT1-mediated prodrug uptake: a way to breach the blood-brain barrier? Ther Deliv. 4(3):281–284.
   PubMedGoogle Scholar
• Shen J, Zhan C, Xie C, Meng Q, Gu B, Li C, Zhang Y, Lu W. 2011. Poly(ethylene glycol)-block-poly (d, l-lactide acid) micelles anchored with angiopep-2 for brain-targeting delivery. J Drug Targeting. 19(3):197–203.
   PubMed Web of Science ®Google Scholar
• Sim T, Lim C, Hoang NH, Oh KT. 2017. Recent advance of pH-sensitive nanocarriers targeting solid tumors. J Pharma Investig. 47(5):383–394.
   Google Scholar
• Tao Y, Cui FD, Choi MK, Cho JW, Chung SJ, Shim CK, Kim DD. 2007. Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation. Int J Pharm. 338(1-2):317–326.
   PubMedGoogle Scholar
• Wang M, Sun J, Zhai Y, Lian H, Luo C, Li L, Du Y, Zhang D, Ding W, Qiu S, et al. 2015. Enteric polymer based on pH-responsive aliphatic polycarbonate functionalized with vitamin E to facilitate oral delivery of tacrolimus. Biomacromolecules. 16(4):1179–1190.
   PubMed Web of Science ®Google Scholar
• Yanagida O, Kanai Y, Chairoungdua A, Kim DK, Segawa H, Nii T, Cha SH, Matsuo H, Fukushima J, Fukasawa Y, et al. 2001. Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta. 1514(2):291–302.
   PubMed Web of Science ®Google Scholar
• Yin YM, Cui FD, Mu CF, Choi MK, Kim JS, Chung SJ, Shim CK, Kim DD. 2009. Docetaxel microemulsion for enhanced oral bioavailability: Preparation and in vitro and in vivo evaluation. J Controlled Release. 140(2):86–94.
   PubMed Web of Science ®Google Scholar
• Yin Z, Jiang H, Syversen T, Rocha JBT, Farina M, Aschner M. 2008. The methylmercury-l-cysteine conjugate is a substrate for the L-type large neutral amino acid transporter&nbsp. J Neurochem. 107(4):8.
   Web of Science ®Google Scholar
• Yong WC, Lee J, Lee SC, Huh KM, Park K. 2004. Hydrotropic agents for study of in vitro paclitaxel release from polymeric micelles. J Control Release. 97(2):249–257.
   PubMed Web of Science ®Google Scholar
• You HB, Park K. 2011. Targeted drug delivery to tumors: myths, reality and possibility. J Control Release. 153(3):198–205.
   PubMed Web of Science ®Google Scholar